Launching on Bittensor

Synthetic Human
Genomic Intelligence

NIOME generates AI-powered synthetic genomic data that's statistically indistinguishable from real DNA—at any scale, without ethical or legal barriers. A Bittensor subnet unlocking the $44B precision medicine market.

Join Discord Read the Whitepaper
The Crisis

The Data Bottleneck Killing Precision Medicine

Drug development is flying blind. Pharmaceutical companies and research institutions need datasets of 100,000+ genomes—sometimes millions—to identify meaningful genetic patterns.

10,000 Industry standard dataset
100,000+ What's actually needed

Real genomic data is locked behind consent requirements, privacy regulations, and the shadow of breaches like 23andMe's 2023 disaster. The result: life-saving research stalls while patients wait.

NIOME breaks the bottleneck.

We generate synthetic genomic profiles that preserve the statistical patterns and correlations of real DNA—without containing any actual person's data. Unlimited scale. Zero privacy risk.

The Solution

Synthetic Genomic Intelligence at Scale

NIOME generates AI-powered synthetic genomic data that mimics real DNA without compromising privacy—enabling large-scale research without ethical or legal concerns.

Simulate

Generate statistically accurate synthetic genomic profiles that preserve the patterns and correlations of real DNA data.

Discover

Unlock insights for drug response prediction, population genetics, and personalized medicine at unprecedented scale.

Evolve

Continuously improve models through decentralized AI, creating a self-reinforcing cycle of genomic intelligence.

Bittensor Subnet

Decentralized Genomic Intelligence

NIOME operates as a subnet on Bittensor—the decentralized AI network where machine learning is incentivized through token rewards.

Miners

Run genomic simulation models to generate synthetic DNA profiles. Earn $TAO emissions proportional to the quality and novelty of your synthetic data.

Mining Documentation →

Validators

Evaluate synthetic data quality using statistical benchmarks and biological plausibility checks. Stake $TAO to participate.

Validator Requirements →

Researchers & Pharma

Access privacy-safe genomic datasets via API. Request custom cohorts—specific population genetics, disease variants, or pharmacogenomic profiles.

Request API Access →
Real-World Application

From Synthetic Data to Personalized Medicine

Here's how it works in practice: CYP2D6 is a gene that controls how your body metabolizes common drugs—from codeine to antidepressants.

NIOME miners generate thousands of synthetic genomic profiles with realistic CYP2D6 variations. Validators verify these profiles match real-world population distributions.

The result: AI models that can predict how YOUR unique genetics will respond to a medication, trained on datasets that would be impossible to assemble ethically with real genomes.

Enterprise Solutions

Synthetic Genomic Data for Pharmaceutical Research

Unlock the full potential of precision medicine with customised synthetic genomic datasets—built for safety, precision, and scale.

Safety

Zero Re-identification Risk

Synthetic genomes contain no real patient data. No GDPR burden. No HIPAA compliance overhead. No breach liability.

Precision

Statistically Indistinguishable

Our synthetic data preserves the statistical distributions, allele frequencies, and genetic correlations of real populations.

Scale

100K to Millions of Genomes

Generate datasets at any scale required for statistically significant research. No consent bottlenecks. No IRB delays.

Phenotypic Data Models

Build and train AI models that predict phenotypic outcomes from genomic data.

  • Drug response prediction models
  • Disease risk stratification algorithms
  • Pharmacogenomic profiling systems
  • Biomarker discovery pipelines

Safely Sourced Genomic Data

Our data generation pipeline is built on privacy-first principles.

  • No real patient identifiers—ever
  • Validated against diverse population cohorts
  • GDPR and HIPAA compliant by design
  • Audit trails for regulatory submissions

In-Depth Analysis

Custom cohort generation with granular control over population characteristics.

  • Ancestry-specific variant distributions
  • Rare variant enrichment for edge cases
  • Disease-specific genetic architectures
  • Linkage disequilibrium preservation

API Access & Integration

Seamless integration with your existing research infrastructure.

  • RESTful API with comprehensive documentation
  • VCF, PLINK, and custom format exports
  • Batch generation for large-scale studies
  • Dedicated support for enterprise clients

Ready to Accelerate Your Research?

Get access to customised synthetic genomic datasets tailored to your research requirements.

Contact Enterprise Sales
Backed By

Industry Leaders

This partnership is a milestone for genomics and decentralized AI. By combining world-class technical expertise with our mission to handle genomic data in the safest way possible, we're opening a new chapter for healthtech.

Aldo de PapeCEO, Genomes.io

Genomes serves as a trustless, transparent counterweight to centralized companies like 23andMe. Using synthetic data from the NIOME subnet, we can advance the $44 billion genomics industry in the safest way possible.

Mike GrantisCEO, General TAO Ventures

The convergence of human genomics and decentralized AI opens a new chapter for healthtech. This partnership showcases how Bittensor can advance medical research without compromising privacy.

Evan MalangaCRO, Yuma
Questions

Frequently Asked Questions

Yes. Synthetic data that accurately preserves statistical distributions and genetic correlations can train machine learning models just as effectively as real data—sometimes better, because you can generate edge cases and rare variants that are underrepresented in real datasets.

Synthetic genomes don't correspond to any real person. There's no consent to obtain, no re-identification risk, and no GDPR/HIPAA compliance burden. You can't breach data that never existed.

In 2023, 23andMe suffered a data breach exposing millions of users' genetic information. Unlike a password, you can't change your DNA—those users face lifetime privacy risks. NIOME's synthetic approach eliminates this category of risk entirely.

If you can run a Bittensor miner, you can run NIOME. Our subnet launches in Q1 2025—join the waitlist for documentation and testnet access.

Q1 2025. Join the waitlist to get notified of testnet access and mainnet launch.

Enterprise clients can access customised synthetic genomic datasets through our API. Contact our enterprise team to discuss your specific research needs.

Get Started

Ready to build the future of genomic intelligence?

Join Discord

Connect with the community